11th circ ‘eviscerated’ orphan drug rights, says petition
New Jersey pharma company Jacobus Pharmaceutical has asked the US Supreme Court to review an 11th Circuit verdict that it claims “eviscerated” decades of precedent regarding Orphan Drug Act (ODA) exclusivity.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
1 July 2021 Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
23 May 2021 The US House of Representatives has passed a bill to amend exclusivity laws for drugs on the US Food and Drug Administration’s orphan drugs list.
1 July 2021 Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
23 May 2021 The US House of Representatives has passed a bill to amend exclusivity laws for drugs on the US Food and Drug Administration’s orphan drugs list.
1 July 2021 Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
23 May 2021 The US House of Representatives has passed a bill to amend exclusivity laws for drugs on the US Food and Drug Administration’s orphan drugs list.